معرفی
Daniel Markl is a Lecturer and Chancellor's Fellow at the University of Strathclyde's Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), serving as Associate Director of the Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC). His research integrates advanced measurement techniques with digital process design to revolutionize pharmaceutical manufacturing.
His academic journey includes:
- BSc in Telematics (2010), Graz University of Technology
- MSc in Telematics with neural networks focus (2012), Graz University of Technology (including Erasmus Mundus study at Lund University)
- PhD in Chemical Engineering (2015), Graz University of Technology
Markl's research centers on continuous manufacturing of solid oral dosage forms, innovative process analyzers (particularly terahertz imaging/spectroscopy), and digitally designed drug products. His lab employs optical coherence tomography, X-ray computed tomography, and machine learning to characterize material properties and model tablet disintegration/swelling processes. Key focus areas include real-time release testing, material attribute-process parameter linkages, and rapid formulation design for targeted drug release.
Recent publications demonstrate advancements in spatially-resolved tablet dissolution analysis and real-time polymorphic monitoring during tabletting, reflecting strong trends toward in-line process analytical technologies and fundamental understanding of solid dosage form physics.
His scientific recognition includes:
- AAPS Pharmaceutical Research Meritorious Manuscript Award (2019)
- Best Poster Award (2016)
Markl actively supervises students (5 supervised works documented) and leads major research initiatives including the CERSI for Digital Transformation (Principal Investigator) and EPSRC MediForge Hub (Co-investigator), securing substantial funding for cyberphysical manufacturing platforms. His work directly supports UN Sustainable Development Goals related to health innovation.
He directs TheMarklLab and contributes to CMAC's industry-academic collaborations, focusing on mechanistic modeling of disintegration processes and developing cutting-edge process monitoring solutions for next-generation pharmaceutical manufacturing.
